Drugs / PHI-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04678102 | Dec 2020 → Dec 2023 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, refractory malignant neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04842370 | Jun 2020 → May 2022 | acute myeloid leukemia | Seoul National University Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04842370 ↗ |
| Action | Inhibit | “PHI-101 is a CHK2 inhibitor” NCT04678102 ↗ |
| Modality | Small molecule | — CHEMBL4802136 ↗ |
| Route | Oral | “daily oral administration of PHI-101” NCT04678102 ↗ |
| Target | CHEK2 | “PHI-101 is a CHK2 inhibitor” NCT04678102 ↗ |